Journal
INFECTION
Volume 46, Issue 3, Pages 431-434Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s15010-018-1125-5
Keywords
Ceftolozane-tazobactam; Pseudomonas aeruginosa; Hematologic malignancy; Hematopoietic-cell transplant
Categories
Ask authors/readers for more resources
Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available